News Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
10.33 ^USD	-2.09%		-7.93%	-27.20%

Mar. 18	JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	MT
Mar. 05	Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amicus Therapeutics : ESG Report	Mar. 20	PU
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report	Mar. 20	AQ
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	Mar. 18	MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	Mar. 05	MT
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024	Mar. 04	AQ
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024	Mar. 01	AQ
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	Feb. 28	MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04	Feb. 28	MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 28	CI
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates	Feb. 28	AQ
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Amicus Therapeutics : Fourth Quarter and Full Year 2023 Results Conference Call and Webcast	Feb. 27	PU
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024	Feb. 15	AQ
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti + Opfolda at the 20th Annual WORLDSymposium	Feb. 09	AQ
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing	Feb. 08	MT
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™	Feb. 08	AQ
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024	Feb. 01	AQ
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing	Jan. 24	MT
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing	Jan. 18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Summary

Filters